Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05541796
Other study ID # WVI/2022/01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 19, 2022
Est. completion date December 31, 2023

Study information

Verified date July 2023
Source Waring Vision Institute
Contact Jessica Stubing
Phone 843-216-2020
Email jstubing@waringvision.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tecnis Symfony Optiblue (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus intraocular lens (IOL) that provides a continuous range of clear vision at far and intermediate. Tecnis Synergy™ IOL (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles. These IOLs are approved/licensed for use and are not investigational. The present study intends to evaluate the clinical outcomes and patient satisfaction following contralateral implantation of Tecnis Synergy and Symfony Optiblue in cataract patients. The investigator hypothesizes that the contralateral implantation of these two lenses will allow a good proportion of patients to be spectacle independent at distance, intermediate, and near. The findings of this study may help the surgeons make better decisions on the choice of IOL in the future.


Description:

Presbyopia-correcting intraocular lenses (IOLs), including multifocal and extended depth of focus (EDOF) IOLs, have revolutionized the field of refractive cataract surgery by providing good vision at multiple distances and spectacle independence. While multifocal IOLs provide good visual acuity at various distances, increased incidence of photic phenomena (haloes, glare, starbursts, etc.) associated with multifocal IOLs is a cause of dissatisfaction among patients. EDOF IOLs, on the other hand, are based on the principle of creating a single-elongated focal point to enhance the depth-of-focus (DOF) and eliminate the overlapping of near and far images caused by traditional multifocal IOLs, thus minimizing the halo effect. Recent developments in IOL technologies focus on finding the best compromise between the range of visual rehabilitation and the induction of postoperative photic phenomena and contrast sensitivity reduction. One of these developments is the Tecnis Synergy™ IOL, which combines an EDOF profile with a multifocal diffractive design, to obtain continuous high-contrast vision from far through near, even in low-lighting conditions (Tecnis Synergy, Johnson & Johnson Vision, Santa Ana, CA, Unites States) without the visual gaps caused by the trifocal technology. Preliminary data with Tecnis Synergy IOLs in European populations are quite encouraging. In some cases, a combination of two different IOLs has been implanted to capitalize on the strengths and mitigate the weaknesses of each. Thus, the present study aims to evaluate the clinical outcomes and patient satisfaction following implantation of a combination of Tecnis Synergy and Tecnis Symfony OptiBlue IOLs in a US-based population of cataract surgery patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion Criteria: - Age 40 years or older - Requiring bilateral cataract surgery, wish to achieve spectacle independence. - Are suitable candidates for Tecnis Synergy and Tecnis Symfony IOLs - Have predicted postoperative astigmatism = 0.75 D - Willing to provide written informed consent and adhere to study requirements Exclusion Criteria: - History of ocular surgery, including laser refractive surgery - History of ocular trauma - Patients planning for any concomitant ocular procedure at the time of cataract surgery (including MIGS) other than incisional correction of astigmatism as the time of surgery - Ocular comorbidities including glaucoma, macular degeneration, corneal scars, or any other condition that might limit the ability to achieve 20/20 visual acuity. - Unwillingness to provide written informed consent, - Disability to understand and/or fill the patient questionnaire, - Pregnancy or lactation. - Any patient who meets enrollment criteria but subsequently experiences an intraoperative complication or does not undergo surgery with implantation of the intended pair of IOLs will also be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Intraocular lens
Tecnis Symfony Optiblue (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is a violet light filtering extended depth of focus IOL that provides a continuous range of clear vision at far and intermediate. Tecnis Synergy™ IOL (Johnson & Johnson Vision, Santa Ana, CA, Unites States) is another latest United States Food and Drug Administration (USFDA) approved IOL, designed to provide good acuity at far through near distances, reducing the need for spectacles.

Locations

Country Name City State
United States Waring Vision Institute Mount Pleasant South Carolina

Sponsors (2)

Lead Sponsor Collaborator
George O. Waring IV Johnson & Johnson Surgical Vision, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Binocular distance-corrected intermediate visual acuity under mesopic conditions Binocular mean logMAR distance-corrected intermediate visual acuity (DCIVA, 66 cm) Postoperative 6 months
Other Binocular distance-corrected near visual acuity under mesopic conditions Binocular mean logMAR distance-corrected near visual acuity (DCNVA, 40 cm) Postoperative 6 months
Other Binocular distance-corrected very near visual acuity under mesopic conditions Binocular mean logMAR distance-corrected very near visual acuity (DCVNVA, 33 cm) Postoperative 6 months
Other Binocular uncorrected distance visual acuity under mesopic conditions Binocular mean logMAR uncorrected distance visual acuity Postoperative 6 months
Other Binocular uncorrected intermediate visual acuity under mesopic conditions Binocular mean logMAR uncorrected intermediate visual acuity (UIVA, 66 cm) Postoperative 6 months
Other Binocular uncorrected near visual acuity under mesopic conditions Binocular mean logMAR uncorrected near visual acuity (UNVA, 40 cm) Postoperative 6 months
Other Binocular uncorrected very near visual acuity under mesopic conditions Binocular mean logMAR uncorrected very near visual acuity (UVNVA, 33 cm) Postoperative 6 months
Primary Binocular distance-corrected intermediate visual acuity under photopic conditions. Mean logMAR binocular distance-corrected intermediate visual acuity (DCIVA, 66 cm). Postoperative 6 months
Primary Binocular distance-corrected near visual acuity under photopic conditions. Mean logMAR binocular distance-corrected near visual acuity (DCNVA, 40 cm). Postoperative 6 months
Primary Binocular distance-corrected very near visual acuity under photopic conditions. Mean logMAR binocular distance-corrected very near visual acuity (DCVNVA, 33 cm). Postoperative 6 months
Secondary Binocular uncorrected intermediate visual acuity under photopic conditions Mean logMAR binocular uncorrected intermediate visual acuity measured at 66 cm Postoperative 6 months
Secondary Binocular uncorrected near visual acuity under photopic conditions Mean logMAR binocular uncorrected near visual acuity measured at 40 cm Postoperative 6 months
Secondary Binocular uncorrected very near visual acuity under photopic conditions Mean logMAR binocular uncorrected very near visual acuity measured at 33 cm Postoperative 6 months
Secondary Binocular uncorrected distance visual acuity under photopic conditions Mean logMAR binocular uncorrected distance visual acuity Postoperative 6 months
Secondary Subjective assessment of patient satisfaction and other patient-reported outcomes using visual symptoms questionnaire (PRVSQ) Subjective assessment of patient satisfaction with the surgery and other patient-reported outcomes using a patient-reported visual symptoms questionnaire (PRVSQ) Postoperative 6 months
Secondary Subjective assessment of patient satisfaction and other patient-reported outcomes using spectacle independence questionnaire (PRSIQ) Subjective assessment of patient satisfaction with the surgery and other patient-reported outcomes using a patient-reported spectacle independence questionnaire (PRSIQ) Postoperative 6 months
See also
  Status Clinical Trial Phase
Completed NCT04685538 - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification. Phase 3
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting NCT05518539 - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting NCT05271942 - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods N/A
Active, not recruiting NCT04778501 - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia N/A
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT03751033 - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings N/A
Completed NCT02529488 - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00 N/A
Completed NCT04539548 - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract Phase 3
Completed NCT03740659 - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery Phase 2
Completed NCT03494257 - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification N/A
Completed NCT05119127 - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome. N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03713268 - Intraoperative OCT Guidance of Intraocular Surgery II
Completed NCT03739528 - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery Phase 3
Completed NCT02888210 - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery Phase 3
Completed NCT03356847 - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery N/A
Completed NCT04332640 - Clinical Evaluation of the Next Generation Phaco System N/A
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT03050697 - Evaluation of the Safety and Performance of the HARMONI® Toric Lens N/A